請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27724
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳祈安 | |
dc.contributor.author | Chia-Yen Huang | en |
dc.contributor.author | 黃家彥 | zh_TW |
dc.date.accessioned | 2021-06-12T18:17:22Z | - |
dc.date.available | 2007-09-12 | |
dc.date.copyright | 2007-09-12 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-08-29 | |
dc.identifier.citation | 1. 國民健康局『癌症登記工作小組』公告之2004年十大死因。
網址:http://crs.cph.ntu.edu.tw/crs-c/index.htm 2. Rustin GJ. Tumour markers for ovarian cancer. Eur J Cancer 1992;28:2-3. 3. Pfleiderer A. Diagnosis and staging of ovarian cancer. J Cancer Res Clin Oncol 1984;107:81-8. 4. Gonzalez-Diego P, Lopez-Abente G, Pollan M, Ruiz M. Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur J Cancer 2000;36:1816-24. 5. Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat 2000;5:221-31. 6. Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982;59:576-82. 7. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20. 8. Malkasian GD, Jr., Melton LJ, 3rd, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984;149:274-84. 9. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-70. 10. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. Journal of the National Cancer Institute 1992;84:1512-1517. 11. Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.. Br J Cancer 2003;88:1963-70. 12. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96:11531-6. 13. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40. 14. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994;269:805-8. 15. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40. 16. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6. 17. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28. 18. McGuire WP, Rowinsky EK. Old drug revisited, new drugs and experimental approaches in ovarian cancer therapy. Semin Oncol 1991;18:255-269. 19. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6. 20. Yamamoto, K., Kikuchi, Y., Kudoh, K., and Nagata, I. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 2000;126:168-72. 21. Vikhanskaya, F., Marchini, S., Marabese, M., Galliera, E., and Broggini, P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res. 2001;61:935-8. 22. O'Gorman, D. M., and Cotter, T. G. Molecular signals in anti-apoptotic survival pathways. Leukemia. 2001;15:21-34. 23. Dumontet C, Sikic BI. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-1070. 24. Sobin LH WC. UICC TNM Classification of Malignant Tumors, 5th ed. New York, New York: Wiley-Liss, 1997. 25. Hoskins et al: Principles and practice of gynecologic oncology. 4th edition. pp935. Lippincott Williams and Wilkins, 2005. 26. Huang CY, Cheng WF, Lee CN, SU YN, Chien SC, Tzeng YL, Hsieh CY, Chen CA. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006;26:4721-8. 27. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002;8:3520-6. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/27724 | - |
dc.description.abstract | 目的:上皮性卵巢癌是所有婦科癌症之中死亡率最高的疾病之一。對於上皮性卵巢癌的標準治療方式為盡可能最大範圍的減積手術,再追加輔助性化學治療。臨床上在處理上皮性卵巢癌的病人時常常會因為腫瘤對化學治療容易產生抗藥性,導致預後不佳。Mesothelin-一種由間質細胞(mesothelial cell)分泌的醣蛋白,最早是由間質細胞、間質細胞瘤,以及卵巢癌細胞中所發現。Mesothelin確切的功能,至今仍無法得知。這個研究的目的,在於評估上皮性卵巢癌組織中mesothelin表現的多寡,是否會和臨床上病人對化學治療的反應有所相關。
方法:我們總共收集了九十八名上皮性卵巢癌的病人,他們都接受手術及術後輔助性化學治療。如果是進展性疾病,或是在完成化學治療後的六個月內復發者,我們將這些病人定義為對化學治療具抗藥性組;病人如果在完成化學治療後,大於六個月後才復發,以及尚未復發者,我們將這些病人定義為對化學治療具敏感性組。我們收集這些病人臨床以及病理學上的因子,採用quantitative competitive RT-PCR(QC RT-PCR)以及real-time quantitative RT-PCR(RTQ RT-PCR)方法來測量卵巢癌組織中mesothelin基因的表現量,並與臨床資料及病人的預後做相關分析。 結果:在卵巢癌的組織中,對化學治療具抗藥性的一組,比對化學治療具敏感性的一組,其mesothelin的表現量較高(p<0.05)。此外,分化較差的腫瘤,也比分化較佳的腫瘤表現出更多的mesothelin(p<0.05)。表現過量mesothelin的病人,比表現正常量mesothelin的病人,有較短的無病存活期(10.8月 v.s. 20.2月; p<0.05)。此外,在漿液性上皮性卵巢癌的病人之中,表現過量mesothelin的病人,比mesothelin表現量正常的病人,有較短的整體存活期(Log Rank Test: p<0.01)。 結論:上皮性卵巢癌組織中,mesothelin表現的多寡,可以用來評估病人對化學治療是否會產生抗藥性。 | zh_TW |
dc.description.abstract | Objective: Ovarian cancer is one of the leading cause of death among all gynecologic malignancies. The standard treatment of epithelial ovarian cancer (EOC) includes maximally debulking surgery followed by adjuvant chemotherapy. However, resistance to chemotherapy is an important issue while managing patients with EOC. Mesothelin, a secreted glycoprotein, was originally identified on mesothelial cells, mesotheliomas and ovarian cancers. The definite function of mesothelin is still to be clarified. This study is to investigate if the expression levels of mesothelin would correlate with chemotherapeutic response of patients with EOC.
Methods: Ninety eight patients with EOC received operation and postoperative adjuvant chemotherapy were enrolled. Patients with progressive disease or with recurrence within 6 months after completion of chemotherapy were defined as resistant group. Patients without recurrence or with recurrence more than 6 months after completion of chemotherapy were defined as sensitive group. Their clinical and pathologic items were recorded. Expression of mesothelin in ovarian cancer tissue was measured by quantitative competitive RT-PCR (QC RT-PCR) and real-time quantitative PCR (RQ-PCR) methods. The results were correlated to clinical data and outcome of these patients. Results: The expression of mesothelin in ovarian cancer tissue was significantly higher in patients of resistant group than in sensitive group (p<0.05). In addition, high grade tumors also expressed higher level of mesothelin than those with low grade tumors (p<0.05 ). Patients with mesothelin over-expression had significantly shorter disease free survival than those with normal expression of mesothelin (10.8 months v.s.20.2 months; p<0.05). Patients with over-expression of mesothelin had a poorer overall survival than those with normal expression of mesothelin in serous type of EOC (Log Rank Test: p<0.01). Conclusions: The expression level of mesothelin in ovarian cancer tissue might be a predictor for the possibility of chemotherapy resistance for patients of EOC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-12T18:17:22Z (GMT). No. of bitstreams: 1 ntu-96-P94421007-1.pdf: 620423 bytes, checksum: 3f53687ccbc3c8d0f1c68429612da1ba (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 一、中文摘要......................2
二、緒論..........................4 三、研究方法與材料................8 四、結果.........................13 五、討論與展望...................18 六、英文摘要.....................21 七、參考文獻.....................23 八、圖表.........................26 | |
dc.language.iso | zh-TW | |
dc.title | Mesothelin與上皮性卵巢癌病人其化學治療反應的關聯性 | zh_TW |
dc.title | Correlation between Mesothelin and Chemotherapeutic Response in Patients of Epithelial Ovarian Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 謝長堯 | |
dc.contributor.oralexamcommittee | 鄭文芳,葉坤輝 | |
dc.subject.keyword | 上皮性卵巢,預後,mesothelin,化學治療,抗藥性, | zh_TW |
dc.subject.keyword | epithelial ovarian cancer,prognosis,mesothelin,chemotherapy,drug-resistance, | en |
dc.relation.page | 38 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-08-29 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 605.88 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。